Steroid trial for COVID brain fog halted early
NCT ID NCT05986422
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the steroid methylprednisolone could improve memory and thinking in people with long COVID. About 96 adults with ongoing memory problems were to receive either the drug or a placebo for six weeks. The trial was terminated early, so we don't know if the treatment works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- methylprednisolone (a steroid that reduces inflammation)
- What this could lead to
- If it had worked, this could point toward a treatment for memory problems after COVID-19.
- What could go wrong
- The trial was terminated early, so we don't have clear results. Steroids like methylprednisolone can have side effects, and it's unknown if they help brain fog.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID-19 SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.